ABOS
Acumen Pharmaceuticals, Inc.
Biotechnology
Market Cap$155M
5Y Perf.-83.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ABOS vs ANVS
Revenue, margins, valuation, and 5-year total return — side by side.
ANVS
Annovis Bio, Inc.
Biotechnology
Market Cap$62M
5Y Perf.-93.4%
ABOS vs ANVS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ABOS | ANVS |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $155M | $62M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-133M | $-29M |
| Total Debt | $30M | $0.00 |
| Cash & Equiv. | $36M | $19.53B |
ABOS vs ANVS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ABOS
ANVS
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Acumen Pharmaceutic… (ABOS) | 100 | 16.5 | -83.5% |
| Annovis Bio, Inc. (ANVS) | 100 | 6.6 | -93.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ABOS vs ANVS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ABOS leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Annovis Bio, Inc. is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
ABOS
Acumen Pharmaceuticals, Inc.
The Income Pick
ABOS carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 1.92
- Lower volatility, beta 1.92, Low D/E 16.3%, current ratio 6.46x
- Beta 1.92, current ratio 6.46x
Best for: income & stability and sleep-well-at-night
ANVS
Annovis Bio, Inc.
The Growth Play
ANVS is the clearest fit if your priority is growth exposure and long-term compounding.
- EPS growth 99.9%
- -76.2% 10Y total return vs ABOS's -87.3%
- 100.4% revenue growth vs ABOS's -57.6%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ANVS | 100.4% revenue growth vs ABOS's -57.6% |
| Quality / Margins | ABOS | 4.3% margin vs ANVS's 0.0% |
| Stability / Safety | ABOS | Beta 1.92 vs ANVS's 2.08 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ABOS | +156.0% vs ANVS's +42.5% |
| Efficiency (ROA) | ANVS | -0.5% ROA vs ABOS's -93.8% |
ABOS vs ANVS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLANVSLAGGINGABOS
ABOSAcumen Pharmaceutical…
2leads
ANVSAnnovis Bio, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs ABOSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ANVS1/1
Valuation MetricsMultiples, price ratios, and targets
ANVS2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ANVS6/6
Total Returns1Y, 3Y, 5Y total returns with dividends
ABOS5/6
Risk & VolatilityBeta, volatility, and downside exposure
ABOS2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ANVS leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ABOS and ANVS operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | ABOSAcumen Pharmaceut… | ANVSAnnovis Bio, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$137M | -$30M |
| Net IncomeAfter-tax profit | -$133M | -$29M |
| Free Cash FlowCash after capex | -$124M | -$853M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +12.0% | +16.7% |
ANVS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
ANVS leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | ABOSAcumen Pharmaceut… | ANVSAnnovis Bio, Inc. |
|---|---|---|
| Market CapShares × price | $155M | $62M |
| Enterprise ValueMkt cap + debt − cash | $149M | -$19.5B |
| Trailing P/EPrice ÷ TTM EPS | -1.50x | -1.63x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 0.84x | 0.00x |
| Price / FCFMarket cap ÷ FCF | — | — |
ANVS leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
ANVS leads this category, winning 6 of 6 comparable metrics.
Profitability & Efficiency
ANVS delivers a -0.7% return on equity — every $100 of shareholder capital generates $-1 in annual profit, vs $-143 for ABOS. On the Piotroski fundamental quality scale (0–9), ANVS scores 2/9 vs ABOS's 1/9, reflecting mixed financial health.
| Metric | ABOSAcumen Pharmaceut… | ANVSAnnovis Bio, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -143.1% | -0.7% |
| ROA (TTM)Return on assets | -93.8% | -0.5% |
| ROICReturn on invested capital | -42.3% | — |
| ROCEReturn on capital employed | -44.8% | -0.3% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 2 |
| Debt / EquityFinancial leverage | 0.16x | — |
| Net DebtTotal debt minus cash | -$6M | -$19.5B |
| Cash & Equiv.Liquid assets | $36M | $19.5B |
| Total DebtShort + long-term debt | $30M | $0 |
| Interest CoverageEBIT ÷ Interest expense | -30.95x | — |
ANVS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
ABOS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ABOS five years ago would be worth $1,274 today (with dividends reinvested), compared to $797 for ANVS. Over the past 12 months, ABOS leads with a +156.0% total return vs ANVS's +42.5%. The 3-year compound annual growth rate (CAGR) favors ABOS at -19.2% vs ANVS's -46.4% — a key indicator of consistent wealth creation.
| Metric | ABOSAcumen Pharmaceut… | ANVSAnnovis Bio, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +26.7% | -37.5% |
| 1-Year ReturnPast 12 months | +156.0% | +42.5% |
| 3-Year ReturnCumulative with dividends | -47.2% | -84.6% |
| 5-Year ReturnCumulative with dividends | -87.3% | -92.0% |
| 10-Year ReturnCumulative with dividends | -87.3% | -76.2% |
| CAGR (3Y)Annualised 3-year return | -19.2% | -46.4% |
ABOS leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
ABOS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ABOS is the less volatile stock with a 1.92 beta — it tends to amplify market swings less than ANVS's 2.08 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ABOS currently trades 71.1% from its 52-week high vs ANVS's 41.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ABOSAcumen Pharmaceut… | ANVSAnnovis Bio, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.92x | 2.08x |
| 52-Week HighHighest price in past year | $3.60 | $5.50 |
| 52-Week LowLowest price in past year | $0.96 | $1.48 |
| % of 52W HighCurrent price vs 52-week peak | +71.1% | +41.5% |
| RSI (14)Momentum oscillator 0–100 | 44.7 | 57.5 |
| Avg Volume (50D)Average daily shares traded | 594K | 896K |
ABOS leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ABOSAcumen Pharmaceut… | ANVSAnnovis Bio, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $7.00 | — |
| # AnalystsCovering analysts | 7 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ANVS leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). ABOS leads in 2 (Total Returns, Risk & Volatility).
Best OverallAnnovis Bio, Inc. (ANVS)Leads 3 of 6 categories
Loading custom metrics...
ABOS vs ANVS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ABOS or ANVS a better buy right now?
Analysts rate Acumen Pharmaceuticals, Inc.
(ABOS) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ABOS or ANVS?
Over the past 5 years, Acumen Pharmaceuticals, Inc.
(ABOS) delivered a total return of -87. 3%, compared to -92. 0% for Annovis Bio, Inc. (ANVS). Over 10 years, the gap is even starker: ANVS returned -76. 2% versus ABOS's -87. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ABOS or ANVS?
By beta (market sensitivity over 5 years), Acumen Pharmaceuticals, Inc.
(ABOS) is the lower-risk stock at 1. 92β versus Annovis Bio, Inc. 's 2. 08β — meaning ANVS is approximately 8% more volatile than ABOS relative to the S&P 500.
04Which is growing faster — ABOS or ANVS?
On earnings-per-share growth, the picture is similar: Annovis Bio, Inc.
grew EPS 99. 9% year-over-year, compared to -58. 3% for Acumen Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ABOS or ANVS?
Acumen Pharmaceuticals, Inc.
(ABOS) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Annovis Bio, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABOS leads at 0. 0% versus 0. 0% for ANVS. At the gross margin level — before operating expenses — ABOS leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ABOS or ANVS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ABOS or ANVS better for a retirement portfolio?
For long-horizon retirement investors, Acumen Pharmaceuticals, Inc.
(ABOS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Annovis Bio, Inc. (ANVS) carries a higher beta of 2. 08 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABOS: -87. 3%, ANVS: -76. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ABOS and ANVS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.